Pathogenesis, prevention, and treatment of diabetic nephropathy

Lancet

Volumn 352, Issue 9123, 1998, Pages 213-219

  Cooper, Mark E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; POLYOL; PROTEIN KINASE C; VASOACTIVE AGENT;

ANTIHYPERTENSIVE THERAPY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; GLYCATION; HEMODYNAMICS; HUMAN; HYPERTENSION; METABOLISM; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0032543872     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01346-4     Document Type: Review

References (57)

1. 1 Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hospital Report 1836; 10: 338-40.
2. 2 Kimmelsteil P, Wilson C. Intercapillary lesions in the glomeruli in the kidney. Am J Pathol 1936; 12: 83-97.
3. 3 Editorial. Diabetic nephropathy. Lancet 1951; ii: 974.
4. 4 Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes 1997; 46: S104-11.
5. 5 Mogensen CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080-84.
6. 6 Fioretto P, Mauer M, Brocco E, et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996; 39: 1569-76.
7. 7 Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
8. 8 Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 1993; 342: 883-87.
9. 9 Cooper ME, Jerums G, Gilbert RE. Diabetic vascular complications. Clin Exp Pharmacol Physiol 1997; 24: 770-75.
10. 10 Soulis T, Cooper M, Vranes D, Bucala R, Jerums G. The effects of aminoguanidine in preventing experimental diabetic nephropathy are related to duration of treatment. Kidney Int 1996; 50: 627-34.
11. 11 Wuerth J-P, Bain R, Mecca T, Park G, Cartwright K, Pimagedine Investigator Group. Baseline data from the Pimagedine Action trials. Diabetologia 1997; 40: A548.
12. 12 Goldfarb S, Ziyadeh FN, Kern EF, Simmons DA. Effects of polyolpathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 1991; 40: 465-71.
13. 13 Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
14. 14 Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. The role of angiotensin II and bradykinin in experimental diabetic nephropathy: functional and structural studies. Diabetes 1997; 46: 1612-18.
15. 15 Gilbert RE, Cox A, Wu LL, et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414-22.
16. 16 Rumble JR, Cooper ME, Soulis T, et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 1997; 99: 1016-27.
17. 17 Gruden G, Thomas S, Burt D, et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc Natl Acad Sci USA 1997; 94: 12112-16.
18. 18 Trevisan R, Viberti GC. Sodium-hydrogen antiport, cell function and susceptibility to diabetic nephropathy. In: Mogensen CE, ed. The kidney and hypertension in diabetes mellitus, 3rd edn. Norwell, Massachusetts: Kluwer Academic Publishers, 1997: 215-22.
19. 19 Pietruck F, Spleiter S, Daul A, et al. Enhanced G protein activation in IDDM patients with diabetic nephropathy. Diabetologia 1998; 41: 94-100.
20. 20 Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
21. 21 Parving HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996; 313: 591-94.
22. 22 Allen TJ, Cooper ME, Gilbert RG, Winikoff J, Skinner SL, Jerums G. Serum total renin is increased before microalbuminuria in diabetes (IDDM). Kidney Int 1996; 50: 902-07.
23. 23 Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat. Kidney Int (in press).
24. 24 The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.
25. 25 Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
26. 26 Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973-977.
27. 27 Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991; 34: 164-70.
28. 28 Alaveras AE, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 2: 71-4.
29. 29 Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-88.
30. 30 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
31. 31 Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10 (suppl): 39-45.
32. 32 Lewis EJ, Rohde R, Bain R, for the Collaborative Study Group. A follow-up study of the course of nephropathy in type I diabetes mellitus. Nephrology 1997; 3 (suppl 1): 1222.
33. 33 Parving HH, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49: 1778-82.
34. 34 Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 292-300.
35. 35 Allen TJ, Waldron MJ, Casley D, Jerums G, Cooper ME. Salt restriction reduces hyperfiltration, renal enlargement and albuminuria in experimental diabetes. Diabetes 1997; 46: 119-24.
36. 36 Tikkanen T, Tikkanen I, Rockell M, et al. Dual inhibition of neutral endopeptidase and angiotensin converting enzyme in rats with hypertension and diabetes mellitus. Hypertension (in press).
37. 37 Cooper ME, McNally PG. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus, 4th edn. Norwell, Massachusetts: Kluwer Academic Publishers, 1998: 427-40.
38. 38 Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Long-term effect of lisinoprill and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46: 1182-88.
39. 39 The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-93.
40. 40 Gilbert RE, Jerums G, Allen T, Hammond J, Cooper ME, on behalf of the Melbourne Diabetic Nephropathy Study Group. Effect of different antihypertensive agents on normotensive microalbuminuric patients with IDDM and NIDDM. J Am Soc Nephrol 1994; 5: 377.
41. 41 Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998; 21: 104-10.
42. 42 Mathiesen E, Hommel E, Smith U, Parving H-H. Efficacy of captopril in normotensive diabetic patients with microalbuminuria-8 years follow-up. Diabetologia 1995; 38 (suppl 1): A46.
43. 43 The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
44. 44 Chaturvedi N, Sjolie A-K, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in people with type 1 diabetes. Lancet 1997; 351: 28-31.
45. 45 Agardh CD, Garcia Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185-92.
46. 46 Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81.
47. 47 Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-24.
48. 48 Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576-81.
49. 49 Bakris G. Combination therapy for hypertension and renal disease in diabetics as compared to non-diabetics. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus, 3rd edn. Norwell, Massachusetts: Kluwer Academic Publishers, 1997: 561-68.
50. 50 Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
51. 51 Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomised Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998; 21: 597-603.
52. 52 Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 351: 689-90.
53. 53 Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
54. 54 Editorial. What causes diabetic renal failure? Lancet 1988; i: 1433-34.
55. 55 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-45.
56. 56 Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases - a meta-analysis. Ann Intern Med 1996; 124: 627-32.
57. 57 Gilbert RE, Akdeniz A, Jerums G. Detection of microalbuminuria in diabetic patients by urinary dipstick. Diabetes Res Clin Pract 1997; 35: 57-60.